|
meine Mail & Antwort:
"
Dear Sabrina Martucci Johnson,
I´m a Investor from germany and hold some shares from Cerulean Pharma Inc. in my depot.
Since Daré Bioscience Operations, Inc. has become a wholly-owned subsidiary of Cerulean Pharma Inc., i would like to know what happens to the shares bought at the German stock market? "
Dear X,
Effective as of Thursday, July 20, 2017, a one-for-ten reverse stock split of the combined company’s common stock was effected on Thursday, July 20, 2017.
As a result of the reverse stock split, every ten shares of Cerulean's common stock issued and outstanding prior to the opening of trading on Thursday, July 20, 2017 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.0001. No fractional shares will be issued as a result of the reverse stock split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the reverse stock split will receive a cash payment in lieu thereof. The shares underlying all outstanding options and warrants, including those assumed in connection with the transaction with Daré, will also be adjusted accordingly.
Beginning on July 20, 2017, the common stock of the combined company will continue trading on the NASDAQ Capital Market, but, will reflect the new name "Daré Bioscience, Inc.", the new stock symbol "DARE" and the new number of split adjusted shares. There are approximately 6,047,200 shares of Daré common stock issued and outstanding after the split. The common stock trades under a new CUSIP number, 23666P 101.
For more information regarding Cerulean's reverse stock split, please refer to the definitive proxy statement on Schedule 14A filed by Cerulean with the Securities and Exchange Commission on June 19, 2017.
We hope this helps you and the transfer agent better understand the transaction and the shares you now hold in Daré"
|
Thread abonnieren
